Dr. Jingfang Ju and his research group make the news with their dual-action molecule that successfully destroys treatment-resistant non-small cell lung cancer (NSCLC).
The original news article can be found here and published in FirstWorld Pharma.
The published paper in the journal Molecular Therapy about this study can be found here.